The UK and US have finalized a important commercial pact that will keep zero import taxes on UK pharmaceutical exports going into the US market.
The Terms of the Deal
Under the terms of the agreement, the UK has agreed to increase expenditure on pharmaceuticals through the National Health Service (NHS). This commitment secures that duties on these key products will be held at nothing for a period of the next three years.
This development is in response to recent statements to dramatically increase duties on branded pharmaceutical products, with potential rates mentioned reaching double the cost.
"This agreement between the United Kingdom strengthens the international landscape for new treatments and brings much-needed fairness to American-British drug exports," a release said.
Commercial Importance
Pharmaceuticals represent one of the Britain's largest goods shipped to the United States, which is by far the largest destination for major UK drugmakers.
Export figures indicate that in the one-year period to the end of last September, the UK sold pharmaceutical products totaling billions to the US. This amount represented 17.4% of all goods exports in that period.
"This deal secures work, stimulates funding and paves the way for the UK to become a global hub for medical research," a government official remarked.
Key NHS Changes
The agreement includes several specific commitments from the British government:
- Revised Affordability Limit: The UK will raise the cost ceiling at which it considers new therapies to be prohibitively costly by 25%.
- Higher Drug Budget: There is a aim to double total health service expenditure on drugs from 0.3% of the national economy to 0.6% over the coming ten years.
- Rebate Cap: The sum manufacturers must pay back to the NHS to stay within budget will be capped at fifteen percent. In the past, refunds topped twenty percent.
Industry Background
The deal takes place against a protracted tension between the sector and the UK government over drug pricing and approval rates.
This friction were heightened by claims that American customers were paying several times more for the equivalent treatments than patients in the other developed nations.
Recently, several major manufacturing plans in the UK have been paused or abandoned, while major funding commitments have been directed toward US facilities.
One official publicly accepted that the NHS needed to invest a greater share on treatments, noting that its budget allocation on drugs had declined as a share of its total funding over the past decade.
